Research Status Of Direct Acting Antivirals Agent In Treatment Of Chronic Hepatitis C

Background:Our country is the country with high infection rate of Hepatitis C virus(HCV),but the public cognitive for Chronic Hepatitis C is generally low.Since the hidden onset of the hepatitis c,people with HCV infection's clinical symptom is not obvious,that lead to diagnosis and treatment of HCV infection accessibility is low.Long-term HCV infection can cause serious damage to the liver function,further development will even cause liver cirrhosis and Hepatocellular Carcinoma and liver failure.According to the WHO,about 130 million to 150 million people worldwide suffer from chronic HCV infection,in the next 5-10 years,HCV related liver diseases will continue to increase.Traditional treatment for Chronic Hepatitis C has low sustained virological response,high rate of side effects,and the treatment effect is poor.Since the come oue of the direct antiviral drugs in 2011,the treatment of Chronic Hepatitis C has achieved rapid development,at the same time,the research of direct antiviral drugs for HCV is also more and more.Objective:So as to provide some references for the clinical treatment of Chronic Hepatitis C by ireview current research in the direct-acting antiviral agents in treatment of chronic hepatitis C.Methods:In“Chronic Hepatitis C?DAA?direct acting antivirals agent?resistance or liver cirrhosis”and other keywords search to fing out the related research of the direct acting antivirals agent in treatment of chronic hepatitis C,and make a summary of the DAA classify?therapeutic effect and durg security.Result and conclusion:In recent years,there are a lot of literature research of the Chronic Hepatitis C direct acting antivirals agent.Integrated these results suggest that as the new anti-hepatitis C virus drugs,direct acting antivirals agent has won high sustained virological response rate,short delivery cycle,low recurrence rate,and reduced the incidence of adverse events during,direct acting antivirals agent has great potential in antiviral therapies for HCV-related cirrhosis.But direct acting antivirals agent monotherapy is easy to produce drug resistance,the guideline[1] for anti-HCV therapy suggest the combination of current anti-HCV drugs which represents amulti-target therap.